Codetta

Codetta Bio, founded with the mission to revolutionize life sciences research, focuses on providing a novel multi-omic analysis platform. Utilizing digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsIPCR), Codetta's integrated platform combines reagents, hardware, and software to enable multiplexed, multi-omic liquid biopsy and isolated DNA, RNA, and protein analyses. The company aims to accelerate research and development of next-generation therapies, ultimately enhancing patient care through precision medicine.

Notable figures affiliated with Codetta Bio include experts in biotechnology and life sciences who have contributed to the development of the platform. The company has attracted significant interest from investors focused on advancing medical research technologies. Key achievements include the successful integration of dsPCR and dsIPCR into a single workflow, which has garnered attention for its potential to elevate clinical trials with precise biomarker insights. Codetta Bio's impact lies in its ability to provide comprehensive, accurate biomarker measurements, thereby driving forward the capabilities of precision medicine.